GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmicell Co Ltd (XKRX:005690) » Definitions » EV-to-FCF

Pharmicell Co (XKRX:005690) EV-to-FCF : -643.26 (As of Apr. 16, 2025)


View and export this data going back to 1988. Start your Free Trial

What is Pharmicell Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Pharmicell Co's Enterprise Value is ₩540,322 Mil. Pharmicell Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₩-840 Mil. Therefore, Pharmicell Co's EV-to-FCF for today is -643.26.

The historical rank and industry rank for Pharmicell Co's EV-to-FCF or its related term are showing as below:

XKRX:005690' s EV-to-FCF Range Over the Past 10 Years
Min: -2512.86   Med: -50.07   Max: 4512.87
Current: -658.26

During the past 13 years, the highest EV-to-FCF of Pharmicell Co was 4512.87. The lowest was -2512.86. And the median was -50.07.

XKRX:005690's EV-to-FCF is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 2.21 vs XKRX:005690: -658.26

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-16), Pharmicell Co's stock price is ₩9180.00. Pharmicell Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₩106.000. Therefore, Pharmicell Co's PE Ratio (TTM) for today is 86.60.


Pharmicell Co EV-to-FCF Historical Data

The historical data trend for Pharmicell Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmicell Co EV-to-FCF Chart

Pharmicell Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.15 -79.99 -60.57 60.98 -578.97

Pharmicell Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.98 -2,659.30 -50.05 -170.91 -578.97

Competitive Comparison of Pharmicell Co's EV-to-FCF

For the Biotechnology subindustry, Pharmicell Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmicell Co's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmicell Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Pharmicell Co's EV-to-FCF falls into.


;
;

Pharmicell Co EV-to-FCF Calculation

Pharmicell Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=540322.015/-839.978
=-643.26

Pharmicell Co's current Enterprise Value is ₩540,322 Mil.
Pharmicell Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-840 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmicell Co  (XKRX:005690) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Pharmicell Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9180.00/106.000
=86.60

Pharmicell Co's share price for today is ₩9180.00.
Pharmicell Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩106.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Pharmicell Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Pharmicell Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmicell Co Business Description

Traded in Other Exchanges
N/A
Address
12F Chungho B/D, 3-2 Nonhyun-dong Gangnam-gu, Seoul, KOR, 135-010
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.

Pharmicell Co Headlines

No Headlines